Pinnacle Medicines Raises $89M Series B to Advance Oral Peptide Therapeutics
Biotech has a habit of whispering before it roars. This one feels like it’s clearing its throat. Pinnacle Medicines just pulled in $89M in an oversubscribed Series B, and the room leaned in for a reason. LAV and Foresite Capital co-led the round, with Quan Capital, Hankang Capital, RA Capital Management, Logos Capital, and OrbiMed doubling down. When that many sharp elbows crowd the table, it is not curiosity, it is conviction.
Now follow the thread back, because money is just the echo. The signal sits with Chengzao Sun, Ph.D. and Sandeep Somani, Ph.D., two operators who spent decades inside Johnson & Johnson shaping oral peptide programs before deciding they’d rather build the machine than borrow it. Pair that with Jonathan Wang, CEO, a leader who speaks both science and capital fluently, with OrbiMed and Zai Lab in his rearview, and you start to see the architecture behind the moment.
Pinnacle Medicines is chasing something deceptively simple and brutally hard: turning peptides into pills. Not injections, not clinical rituals, just swallowing biologic-level firepower like it’s part of your morning routine. Their platform blends physics-based molecular simulation, AI-driven design, and advanced peptide chemistry to make that leap feel less like science fiction and more like engineering discipline.
The real play is hiding in plain sight. They are not swinging at unproven biology. They are targeting pathways already validated by blockbuster biologics in immunology and cardiometabolic disease. Translation: reduce the guesswork, keep the upside. If you can deliver the same efficacy without the needle, you are not just competing, you are quietly redefining patient behavior at scale.
And timing? Let’s just say the market has been warming up the stage. Oral peptides are no longer a fringe bet. Big pharma has been placing chips, partnerships are getting louder, and suddenly the idea of biologics without injections feels less rebellious and more inevitable.
The dual footprint across Doylestown and Shanghai is not a branding exercise either. It is a speed play. Talent, capital, development cycles, all running in parallel lanes instead of traffic. In this game, velocity compounds.
What stands out is how clean the story is. Raised $134M since 2024. Built by people who have done the work before. Backed by investors who do not chase noise. And a platform aimed directly at one of the most stubborn bottlenecks in modern therapeutics.
Congratulations to Jonathan Wang, Chengzao Sun, Ph.D., Sandeep Somani, Ph.D., and the entire Pinnacle Medicines team. This is what it looks like when experience meets timing and decides to get a little ambitious.
